Predict your next investment

HEALTHCARE | Drug Delivery
steadymed.com

See what CB Insights has to offer

Stage

Acq - P2P | Acquired

Total Raised

$35M

Valuation

$0000 

About SteadyMed Therapeutics

SteadyMed Therapeutics is a drug delivery therapeutics company engaged in the development for commercialization of its prefilled, size efficient and disposable PatchPump technology. The company's range of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner.

SteadyMed Therapeutics Headquarter Location

2410 Camino Ramon Suite 350

San Ramon, California, 94583,

United States

925-272-4999

Latest SteadyMed Therapeutics News

Immune Regulation Ltd Appoints Jonathan Rigby as Chief Executive Officer

Mar 27, 2020

Based in the U.S., Jonathan is an experienced CEO with three productive decades of pharmaceutical, biotech and drug delivery technology value creating achievements. In 2011 he became the CEO of SteadyMed Therapeutics Inc. and focused the company on the development of drug device combination products to treat Pulmonary Hypertension. He led the company through a Nasdaq listing in 2015 (Nasdaq: STDY) and a public-to-public company sale to United Therapeutics (Nasdaq: UTHR) in late 2018. In 2006 he cofounded Zogenix, Inc. (Nasdaq: ZGNX) a specialty pharmaceutical company now focused on the development and commercialization of drug products to treat rare diseases and was instrumental in its listing on Nasdaq in 2010. Earlier in his career, Jonathan held commercial and business development positions of increasing responsibility at large pharmaceutical companies including Merck and Bristol Myers Squibb and Profile Therapeutics, now Phillips Medical. Dr. Dominik Escher, Chairman of Immune Regulation said: “We are excited to welcome Jonathan at Immune Regulation. He brings a wealth of experience across many areas of the pharmaceutical industry that are relevant to the prosperity of Immune Regulation. I am confident that he is the ideal candidate to lead the next stage of clinical development of our two key therapies in immune system resetting. I would like also to thank Richard Nagle, our outgoing Chief Executive, for his leadership of the business since 2017." Jonathan Rigby said: “I am delighted to be joining the very talented team at Immune Regulation. The Company has first-in-class immune-resetting therapies with a broad potential to treat autoimmune diseases. For example, IRL201805 and IRL201104 have shown considerable efficacy in preclinical and human clinical studies in rheumatoid arthritis and asthma / severe allergy respectively. We are also in the early stages of assessing the potential of IRL1104 to reduce lung inflammation which may be a consequence in patients infected by the COVID-19 virus.” Immune Regulation Limited is a clinical stage biotech company, pioneering new technologies for regulating and resetting the immune system and developing novel first-in-class therapies for inflammatory and immunological diseases. Existing therapies are designed to suppress the immune system and require chronic dosing to treat the inflammation, frequently causing severe side effects. Immune Regulation’s first in class immune regulating and resetting therapies have demonstrated unique efficacy and safety in pre-clinical and human studies without suppressing the immune system. These therapies exhibit short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies. At Immune Regulation our aim is to develop novel, safe and effective therapies that reset the immune system, transforming the lives of patients with inflammatory and immunological diseases. Forward-Looking Statements Our statements may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this statement. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SteadyMed Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SteadyMed Therapeutics is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

SteadyMed Therapeutics Patents

SteadyMed Therapeutics has filed 25 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Medical equipment
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/8/2019

5/25/2021

Dosage forms, Medical equipment, Drug delivery devices, Insulin therapies, Ammunition

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/8/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/25/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Dosage forms, Medical equipment, Drug delivery devices, Insulin therapies, Ammunition

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.